Kornimate/medical-research-clean huggingface dataset:
comparison of live birth rate in natural cycle single euploid fet versus without luteal phase support

Conditions: Pregnancy Related; Infertility, Female

Summary: to evaluate whether single euploid embryo transfer in nc without routinely administered lps is non-inferior to nc with routinely administered lps.

in case the study will show that the live birth rate in single euploid nc frozen embryo transfer cycles without lps is not inferior to nc cycles with lps, treatment can be simplified, and participants comfort can be increased.

Eligibility criteria:
inclusion criteria: * age: 18 to 40 years * regular ovulatory cycles * availability of at least one euploid embryo after trophectoderm biopsy for pgt-a on day 5 or day 6 * detection of ovulation by p4 rise \> 1.0 ng/ml after lh surge * p4 value of at least 5 ng/ml on day 4 after ovulation exclusion criteria: * history of repeated pre-menstrual spotting * factors affecting the implantation through anatomical changes of the uterus / ovaries or the tubes (adenomyosis, asherman syndrome, endometriosis, uterine fibroids / polyps, isthmocele with intracavitary fluid presence, hydrosalpinx....)

Keywords: implantation rate infertility pregnancy rate natural cycle luteal phase support live birth progesterone
efficacy of different doses of amino acids in 5aa+crpic water on glucose homeostasis in a healthy population.

Conditions: Healthy

Summary: it has previously been shown that a carbonated water including a defined amount of amino acids and chromium can decrease the postprandial glucose response. in this study, the effect of three different doses of amino acids on glucose excursions after a standardized test meal will be evaluated in healthy subjects. the study will be conducted in a randomized, single center, crossover, double-blinded, placebo controlled design including 25 participants. the primary endpoint of the study is the incremental area under the curve for capillary blood glucose (iauc) within 180 minutes after ingestion of the meal.


Eligibility criteria:
inclusion criteria: * body mass index 18-25 (±0.5) kg/m² * agree to maintain consistent dietary habits and physical activity levels for the duration of the study * healthy as determined by medical history and information provided by the volunteer * willingness to complete questionnaires and follow instructions associated with the study and to complete all visits * has given voluntary, written, informed consent to participate in the study exclusion criteria: * pregnancy or lactation * known type i or type ii diabetes * undetected type i or type ii diabetes (fasting blood glucose \< 6.1 mmol/l at first test day) * use of antibiotics * metabolic diseases and/or chronic gastrointestinal diseases (ibs, crohns etc.) * allergy to test product or placebo ingredients * participants restricted to a vegetarian or vegan diet * intolerance to lactose or gluten * acute infection * individuals who are averse to venous catheterization or capillary blood sampling * alcohol or drug abuse * currently active smokers (tobacco products, and e-cigarettes) * participation in other clinical research trials * individuals who are cognitively impaired and/or who are unable to give informed consent * any other condition which in the pi's opinion may adversely affect the individual's ability to complete the study or its measures or which may pose significant risk to the individual * any medical condition(s) or medication(s) known to significantly affect glucose metabolism. significance to be assessed by the pi * use of medication, over-the-counter medication, natural health products or dietary supplements/probiotics that may affect glucose metabolism is prohibited during this study. significance to be assessed by the pi. participants who are taking allowed prescribed medications must agree to maintain their current method and dosing regimen during the course of the study unless recommended by their physician.

Keywords: diabetes prediabetes blood sugar regulation
fecal microbiota transplantation by oral capsules for hepatic encephalopathy treatment

Conditions: Hepatic Encephalopathy; Dysbiosis

Summary: this interventional study aims to evaluate the safety and efficacy of oral capsule fecal microbiota transplantation (fmt) for treating hepatic encephalopathy refractory to conventional rifaximin and lactulose therapy in patients with liver cirrhosis. patients diagnosed with hepatic encephalopathy refractory to rifaximin and lactulose therapy will be randomized into three groups. while continuing conventional therapy, the first group receives fmt via colonoscopy and oral capsule administration, the second group receives only oral capsule administration, and the third group serves as a control, receiving only conventional therapy. the aims of the study are: to evaluate the efficacy and safety of fmt by oral capsules in cirrhotic patients with hepatic encephalopathy refractory to standard therapy. to evaluate changes in the gut microbiota composition and in the intestinal and systemic inflammatory condition occurring after fmt and if they can be associated with clinical improvement. to evaluate metabolic modifications occurring after fmt and if they can be associated with clinical improvement.


Eligibility criteria:
inclusion criteria: * diagnosis of liver cirrhosis * hepatic encephalopathy of grade \>1 or higher according to west haven classification, persistent or recurrent despite treatment with lactulose/lactitol and rifaximin at adequate doses started at least 30 days before the hepatic encephalopathy episode exclusion criteria: * na \<130 meq /l * creatinine \> 1.3 mg / dl * presence of grade 3 ascites * presence of esophagogastric varices at risk of haemorrhage in the absence of adequate prophylaxis * presence of other possible causes of encephalopathy (cerebral vascular disease, known neurodegenerative or cognitive disorders) * known psychiatric disorders or other causes of brain dysfunction (e.g. hypoglycemia, hyponatremia) * alcohol consumption * diagnosis of hepatocellular carcinoma * contraindication to fecal microbiota transplantation (e.g. pregnancy or breastfeeding) * presence of known intestinal diseases * any clinical condition that, in the opinion of the investigators, may contraindicate the enrollment in the study
use of belatacept to delay tacrolimus initiation in kidney transplant patients with delayed graft function

Conditions: Use of Belatacept in Kidney Transplant Patients

Summary: evaluate the impact of one dose of belatacept in patients with delayed graft function(dgf) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of bk virus(bkv), epstein-barr virus(ebv) and/or cytomegalovirus (cmv) infections.

evaluate the impact of one dose of belatacept in patients with dgf on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of bk virus, ebv and/or cytomegalovirus (cmv) infections. at methodist dallas medical center(mdmc), while providers may choose to initiate belatacept to delay tacrolimus initiation, the impact of this practice on time to renal recovery has not been evaluated. the purpose of this study is to determine if administering belatacept to delay initiation of tacrolimus shortens time to renal recovery in dgf patients

Eligibility criteria:
inclusion criteria: * age ≥18 years * received living or deceased donor kidney transplant during study period * documented dgf exclusion criteria: * multiple organ transplant * recipients with acute rejection present on first biopsy evaluation before first belatacept dose * recipients with a first dose of belatacept after index discharge or tacrolimus initiation
couples lived experience

Conditions: Alzheimer Disease; Dementia of Alzheimer Type

Summary: this is a longitudinal study with regular quantitative assessments of all participants every six months for 3 years. the quantitative portion of the study will recruit couples, consisting of individuals over the age of 65 who are in a committed relationship. both members of the couple must be willing to participate at baseline. the assessment is in two parts. in the first part, each member of the couple will be asked the following: demographic information, mental health history, self-reported physical and emotional health, measures of emotional and mental health, personality, relationship and attachment style, social support and self-efficacy. then each member of the study couple will be asked a series of questions to determine whether they consider themselves a caregiver. if they do, individuals will be asked to respond to additional caregiver questionnaires. follow-ups will occur every six months for the study couples for a total of three years from the baseline visit. each visit, the entire assessment except for demographic questions, will be re-administered to each individual in the couple. at the end of each questionnaire battery, individuals will be screened for cognitive impairment and those who are in the middle to advanced stages of dementia will no longer participate. recruitment will end when 600 individuals (300 couples,150 couples at each site) are enrolled in the longitudinal portion of the study. all study visits will be conducted virtually via zoom or webex video conferencing. analyses will be conducted to determine the association between changes in dyadic relationship and changes in mental health and cognitive outcomes, to elucidate how relationship characteristics impact health and well-being as perceived by each member of the dyad.


Eligibility criteria:
longitudinal portion inclusion criteria: 1. community dwelling older adult aged 65 years or older 2. must speak english as the study measures are not validated in other languages. 3. must express intent to commit to ongoing participation in longitudinal study with assessments every 6 months for 3 years, 4. is part of a couple and their spouse/partner is also willing to participate in the project. all couples, regardless of sexual orientation or gender preference are eligible to participate 5. both members of the couple must cohabitate at the time of enrollment. 6. must have stable internet connection and capability to stream video with audio. 7. a subset of the longitudinal study participants (selected at random) will be invited to be participate in a focus group upon completion of the last (3 year) quantitative assessment. these participants must be willing to have their comments recorded. exclusion criteria: 1. any individual with a prior diagnosis of schizophrenia or other psychotic disorder. 2. individual is unable to complete the informed consent process 3. any individual with a prior diagnosis of a chronic disabling medical condition that would make it impossible to participate in a focus group via zoom or webex.
total motorized spiral enteroscopy trial

Conditions: Small Bowel Disease

Summary: study design prospective bicentric non-controlled clinical trial study purpose - to evaluate the efficacy and safety of novel motorized spiral enteroscopy (nmse) for total enteroscopy in patients with suspected small bowel diseases with an indication for direct visualization of the entire small bowel primary objective rate of total enteroscopy by means of nmse with: 1. a complete anterograde approach 2. or a combined anterograde and retrograde approach secondary objectives * procedural success of anterograde and retrograde approach * procedural time (minutes) * depth of maximum insertion (cm) * diagnostic yield * therapeutic yield * adverse events


Eligibility criteria:
inclusion criteria: * patients with small bowel disease with an indication for a total enteroscopy, e.g.: * overt obscure gastrointestinal bleeding or obscure gastrointestinal bleeding or indeterminate iron-deficiency anaemia and positive video capsule endoscopy (vce) or negative vce in patients who have ongoing bleeding shown by overt bleeding or continued need for blood transfusions * abdominal pain or chronic diarrhoea with positive findings of small bowel imaging examinations * noncontributory ileocolonoscopy and suspicion of crohn's disease on small-bowel cross-sectional imaging modalities or small-bowel capsule endoscopy * further evaluation of known crohn's disease or therapeutic indications in crohn's disease * large polyps (\>10-15mm) in the jejunum and ileum discovered by radiological examination or small-bowel capsule endoscopy in patients with peutz-jeghers syndrome * nonresponsive or refractory coeliac disease exclusion criteria: * - age under 18 years * health status american society of anesthesists classification (asa) 4 * pregnancy * coagulopathy (inr≥2.0, platelets \< 70/nl) * taking anti-platelet agents or anticoagulants (other than aspirin) within last 7 days * any medical contraindication to standard enteroscopy * presence of any intraluminal or extraluminal foreign body in the abdominal cavity * any prior gastric, small bowel or colonic surgery, or implantable devices in these locations (cardiac pacemakers and non-abdominal implants are acceptable) * known or suspected bowel obstruction or stenosis or history of bowel obstruction * known coagulation disorder * known or suspected esophageal stricture or schatzki ring * known gastric or esophageal varices * suspected perforation of the gi tract * known or suspected colonic or ileocecal valve (icv) stricture * inability to tolerate sedation or general anesthesia for any reason * inability to tolerate endotracheal intubation * absence of a signed informed consent

Keywords: endoscopy, motorized spiral enteroscopy
anastrozole administration in elderly hypogonadal men

Conditions: Hypogonadism

Summary: the purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).

it has long been accepted that aging in men is associated with a slow, steady decline in gonadal androgen (male sex hormone) production. several studies have explored androgen replacement, but the safety and efficacy of testosterone administration remains controversial. aromatase inhibitors may provide a particularly useful way to restore normal androgen production in aging men. this study will recruit 150 male volunteers, 60 years of age or older, to be randomized to receive either anastrozole or a placebo for 24 months. six visits are planned over the 96-week treatment period.

Eligibility criteria:
inclusion criteria: * men ages 60 and older * serum testosterone between 150-300 ng/dl * symptoms suggestive of androgen deficiency

Keywords: aging
capsule endoscopy in iron deficiency anaemia

Conditions: Iron Deficiency Anemia; Bowel Cancer

Summary: this project aim to investigate whether wireless capsule endoscopy(wce) has a similar diagnostic yield as conventional endoscopy in detecting the cause of iron deficiency anemia (ida)

ida is common and 90-95% of cases are caused by bleeding from ulcers, tumours or vascular malformations in the oesophagus, stomach, duodenum, small intestine or the large bowel.bleeding from more than one localisation is common. international guidelines recommend bidirectional endoscopy(gastro- and colonoscopy) to detect and treat the source of bleeding. our hypothesis is that wce is non-inferior to the combination of gastroscopy and colonoscopy in locating gi-bleeding and that complete examinations will be achieved in ≥90% of the examinations.

Eligibility criteria:
inclusion criteria: * referred to flexible endoscopy for a verified iron deficiency anaemia exclusion criteria: * unwillingness to participate * not able to provide informed consent * not understanding the instructions * severe cardio-vascular disease new york heart association iii-iv * symptoms of bowel obstruction/previous bowel obstruction * bowel surgery except for end to end anastomosis in the colon * pregnancy
trichomonas vaginalis recurrence among hiv+ women

Conditions: Trichomonas Infections; HIV Infections

Summary: the purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg bid dose for treatment of trichomonas vaginalis (tv) among hiv-infected women.

this is a phase iv equivalency trial as both doses of metronidazole are listed in the the centers for disease control and prevention treatment guidelines for the treatment of t vaginalis.

Eligibility criteria:
inclusion criteria: * female * 18 years or older * hiv-positive * tv positive by either wet preparation or culture * ability to refrain from all alcohol use for 24 hours before and after taking oral metronidazole * willing to take metronidazole treatment exclusion criteria: * pregnant * incarcerated * previously enrolled * currently taking disulfiram * alcoholism or known liver damage * medical contraindications to metronidazole * treated with metronidazole within the previous 14 days * requires treatment for b.v. per amsel's criteria
validation of the french version of the cqr (compliance questionnaire rheumatology)

Conditions: Rheumatoid Polyarthritis

Summary: the purpose of this study is to develop a french language version of the compliance-questionnaire-rheumatology for use in french and francophone rheumatology services


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient is at least 18 years old * the patient has rheumatoid polyarthritis as defined by the acr-eular 2010 criteria, treated orally or subcutaneously with mtx for at least 3 months with a stable (unchanged) dosage for at least 1 month, and a stable (unchanged) route of administration for at least 1 month. and no planned change in methotrexate intake at least until the second study visit. other treatments at the same time are authorized exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * the subject has a contraindication to taking methotrexate (including a patient with a desire to become pregnant).
tailored use of tirofiban for non-st-elevation acute coronary syndrome patients

Conditions: Non-ST Elevation Myocardial Infarction

Summary: investigators aimed to test the beneficial effect of tirofiban, a gpiib/iiia antagonist, for non-st-elevation acute coronary syndrome patients who has high resistance to clopidogrel.

some patients have a poor response to dual antiplatelet therapy (dapt), and it can result in a poor prognosis after percutaneous coronary intervention (pci). devices like ultegra rapid platelet function analyzer (verifynow®) enable us to quantify platelet reactivity quickly in the catheter laboratory. this means that the poor responders to dapt can be identified, and the patients' outcomes can be improved by providing additional antiplatelet agents. tirofiban, a gp iib/iiia inhibitor, is a potent antiplatelet agent which is recommended for non-st-elevation acute coronary syndrome (nste-acs) with high risk at presentation. however, its role is not clear for patients stabilized with standard medical treatment but with a poor responsiveness to dapt. in this study, investigators administered tirofiban on top of dapt to patients with nste-acs undergoing pci who have a high platelet reactivity (hpr) identified by verifynow. to the best of our knowledge, there are few studies conducted with tirofiban for tailored antiplatelet therapy. moreover, this is the first randomized study with nste-acs patients for tailored use of tirofiban under the guidance of platelet reactivity.

Eligibility criteria:
inclusion criteria: * diagnosed with nste-acs who need pci * loaded with aspirin and clopidogrel at least 6 h before the procedure exclusion criteria: * thrombocytopenia (platelet count \<100,000/μl) * history of hemorrhagic stroke * history of ischemic stroke in the recent 2 year * history of major surgery 6 months prior

Keywords: tirofiban resistance to antiplatelet agents
a study to evaluate the efficacy and safety of abiprubart in participants with sjögren's disease

Conditions: Sjögrens Disease

Summary: primary objective of the study is to evaluate the effect of abiprubart on an established systemic disease activity measure for sjögren's disease.

this is a 56-week (24-week randomized double-blind period, 24-week active treatment period, and 8-week safety follow-up period) multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of abiprubart in participants with sjögren's disease with moderate or high systemic disease activity according to the european league against rheumatism (eular) sjögren's syndrome disease activity index (essdai). the objectives of the study are to evaluate efficacy, safety, pharmacokinetics (pk), and pharmacodynamics (pd) of abiprubart compared with placebo across the estimated therapeutic range using different dosing regimens of abiprubart.

Eligibility criteria:
inclusion criteria: * has a diagnosis of sjögren's disease according to 2016 american college or rheumatology (acr)-eular classification criteria. * has essdai value ≥ 5, counting only the biological, hematological, articular, cutaneous, glandular, lymphadenopathy, and constitutional organ domains at screening. * is seropositive at screening for anti-sjögren's-syndrome-related antigen a autoantibodies (ssa) antibodies tested at a central laboratory. * has stimulated whole salivary flow rate at screening of ≥ 0.05 ml/min * weighs at least 40 kg and no more than 150 kg and has a body mass index (bmi) within the range of 18-40 kg/m2. exclusion criteria: * prior exposure to any other anti-cd40/cd154 agent. * diagnosis of sjögren's disease overlap syndromes where another autoimmune rheumatic disease constitutes the principal illness, including fibromyalgia with currently active, inadequately controlled symptoms. * has received cataract surgery, lasik, or other ophthalmologic surgery procedure (e.g., lachrymal plug) in the 6 months prior to screening. * injectable corticosteroids (including intra-articular) within 8 weeks prior to randomization. * has started, stopped or adjusted dose/regimen of medications for treatment of, or known to cause dry mouth/eyes within the 30 days prior to screening or is anticipating change to these treatment regimens during the study. * has history of immunodeficiency (e.g., immune disorders or disorders that result in decreased immunity), including human immunodeficiency virus (hiv). * history of thromboembolic event or a significant risk of future thromboembolic events. * has a known high risk of infection; has a history of chronic or recurrent infectious disease; has any known or suspected active infection, or has had a serious infection requiring hospitalization, or has been treated with iv/im antibiotics for an infection within 8 weeks prior to first dose of study drug or treatment with oral antibiotics for an infection within 2 weeks prior to first dose of study drug.